CASI Pharmaceuticals Settles Arbitration, Retains Evomela® License in China
CASIF has more than doubled off its 52-week low of $0.05 on light trading volume (0.1× avg).
Summary
CASI Pharmaceuticals has settled its arbitration with Acrotech Biopharma, ensuring the continuation of its exclusive license to commercialize Evomela® in China, a critical development for the financially distressed company.
Key Events · Legal and Risk Events · CASIF
-
Arbitration Settled
CASI Pharmaceuticals reached a settlement with Acrotech Biopharma Inc., resolving a dispute over the termination of a license agreement.
-
Evomela® License Reinstated
The settlement rescinds the prior termination, putting the exclusive license agreement for commercializing Evomela® in China back into full force and effect, subject to certain revisions.
-
New Purchase Obligation
The revised agreement includes an obligation for CASI to purchase a minimum number of Evomela® units for certain years.
-
Legal Uncertainty Removed
The parties will now seek dismissal with prejudice of the arbitration, removing a significant legal overhang for the company.
Analysis · CASIF · Life Sciences
This settlement resolves a significant arbitration proceeding concerning the license agreement for Evomela® in China. For a company recently delisted from Nasdaq and facing a "going concern" warning, retaining rights to a key product and removing legal uncertainty is crucial for its operational continuity and potential future revenue streams. The agreement includes an obligation for CASI to purchase minimum units of Evomela®, which represents a new financial commitment.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36% of the 1040 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CASIF was trading at $0.13 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $0.05 to $3.09. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.